Hematopoietic Stem Cell Transplantation Clinical Trial
Official title:
The Collection and Storage of Umbilical Cord Blood for Transplantation
The goal of this study is to collect blood samples from the umbilical cords of newborn
babies, as soon as they are delivered, and to place these samples in the MD Anderson Cord
Blood Bank. Your sample may be included in the National Cord Blood Inventory (NCBI) which is
part of the CW Bill Young Cell Transplantation Program. The NCBI is a federally-supported
program to assist in the collection of cord blood. Cord blood will be made available to
patients through The National Marrow Donor Program (NMDP). These samples may then be offered
to MD Anderson and other institutions for patients who need a bone marrow transplant and do
not have a donor. The MD Anderson Cord Blood Bank will have the rights to release cord blood
units to these institutions around the world according to established bone marrow transplant
donor criteria, for a fee to cover costs.
Cord blood samples that are collected and then do not meet the clinical requirements for
patient use may also be used at MD Anderson or other institutions either for research or for
quality purposes to improve cord blood banking procedures. If not suitable for patient use or
for research purposes, the cord blood unit may be thrown away.
The blood in an unborn baby's umbilical cord contains blood-making cells that could help
treat another person with a life-threatening disease. These cord blood cells may provide
cells for transplants given to patients with marrow diseases such as leukemia. These cord
blood transplants can be done when a patient's cell type (human leukocyte antigen, or HLA,
type) matches the cord blood type. 'Cord blood' is normally thrown away with the umbilical
cord and placenta after the baby is born.
Collection of the cord blood takes place after your new baby is born and the umbilical cord
has been clamped and cut in the normal way. The collection of cord blood takes place from the
part of the cord that is still connected to the placenta, not to your new baby. The cord
blood may be collected 'in-utero': after your baby is delivered but the placenta is still
inside the uterus, or it may be collected 'ex-utero': after the placenta is delivered. The
choice of which method of collection is performed will depend on the preference of your
obstetrician/midwife. Neither method puts you or your baby at any risk of injury. Once the
cord blood is drawn, it becomes the property of the MD Anderson Cord Blood Bank, and you will
not retain any residual interests or rights to this sample.
During the delivery of your baby, your obstetrician has your health and that of your newborn
baby as his or her main concern. If you agree to take part in this study, your doctor and/or
the Cord Blood Bank staff will try to collect the cord blood, but your doctor's main concern
will be the well being of you and your baby. Circumstances may arise which prevent the
collection of your cord blood.
The cord blood that is collected will be taken to the MD Anderson Cord Blood Bank Laboratory,
where it will be tested or sent out for testing to laboratories accredited for doing those
tests as described below.
Just like the donation of blood for transfusion, it is important that cord blood does not
carry any infections that can be passed on. When volunteers donate blood to a blood bank,
they are asked to fill out a confidential questionnaire about their risks for some infections
(like acquired immunodeficiency syndrome (AIDS) caused by the human immunodeficiency virus
(HIV), hepatitis, and/or malaria). You will be asked questions like these in a questionnaire.
You will also be asked some questions about your family medical history, to check for the
chance of an inherited disease that could be passed on with the cord blood. This
questionnaire will be completed within 48 hours of your baby being born, and will take about
15 minutes to complete. This questionnaire is used for screening purposes, and may result in
your cord blood not being suitable for patient use, in which case the cord blood may be used
for research purposes, for quality purposes (to improve cord blood banking procedures), or
discarded. Your medical chart, and that of your infant, will be reviewed to help determine
whether you may have a disease which could be inherited and thus transmitted with the cord
blood to a transplant patient who receives it. Additionally, you will be asked about your
family ethnic/racial background; this information is used to help match the cord blood to the
patients.
A blood sample (about 2 tablespoonfuls) will be drawn from you to test for infectious
diseases including HIV, human T cell Iymphotrophic virus (HTLV), Hepatitis B and C,
cytomegalovirus (CMV), West Nile Virus (WNV), Trypanosoma cruzi (T cruzi, a parasitic
organism that causes Chagas disease) and syphilis. The cord blood unit itself may also be
tested for HIV, HTLV, Hepatitis B and C, CMV, WNV, T. cruzi, syphilis, for bacterial and
fungal infection, and for the blood type (ABO/Rh). This testing will be performed at
accredited testing laboratories. Small samples of your blood and the cord blood (about 2
teaspoonfuls each) will also be frozen and stored separately to screen for diseases in the
future.
If you are delivering your baby in Texas, as per Texas state law, a blood sample will be
taken from your baby by the hospital staff and will be sent to the Department of State Health
Services to be tested for inherited diseases, known as 'Newborn Screening'. You will be asked
to sign a release form which will allow the Department of State Health Services to release
these Newborn screening results to the MD Anderson Cord Blood Bank. Since such diseases may
be passed on through transplant, your donated cord blood unit will not be banked if positive
results are received. The Department of State Health Services will notify your physician of
positive or unclear Newborn screening results.
In addition, the cord blood unit and sometimes the maternal blood sample will be tested for
its HLA type which will be used to identify matches with the transplant patient who needs the
cord blood. This testing will be performed at MD Anderson. A small sample of the cord blood
unit will be sent to the Stemcyte and City of Hope Laboratories in California for more
sophisticated typing to determine whether the cord blood unit might be useful in treating
AIDS patients.
Both your blood and your cord blood are tested for infections, because there are rare
instances where an infection could be found in the mother's blood and yet it has not been
found in the cord blood. It is also possible although uncommon, that an infection could be
found in the cord blood but not in the mother's blood. If the volume of your donated cord
blood is not large enough for banking, testing may not be performed.
All information you provide, as well as the identity of you and your new baby will be kept as
confidential as possible, to the fullest extent allowed by law. While the MD Anderson Cord
Blood Bank has to maintain a link between the cord blood unit and information identifying
you, multiple levels of security will protect this. When the information and blood samples
are collected, they will be given a unique sample number. Nobody except the Principal
Investigator and those designated by the Principal Investigator will have access to any of
your personal information. If your cord blood is released to another institution for
transplant, there will be no way to determine you were the donor as we keep your identity
anonymous. If your donated cord blood cells are used in a transplant, the recipient of your
cord blood cells will not be able to access any of your personal information.
At the time of donation, you will be asked to provide MD Anderson Cord Blood Bank an address
for you and your physician. If any unclear or positive results are found during the testing
of your blood or the cord blood (such as HIV, HTLV, Hepatitis B, Hepatitis C, WNV, Chagas
and/or syphilis), the MD Anderson Cord Blood Bank will notify your physician using the
information you have provided to the Cord Blood Bank. As required by Texas law a confirmed
positive or unclear test for HIV/AIDS or syphilis from your blood or the cord blood will be
reported to the Texas Department of State Health Services. Additionally, the Houston
Department of Health and Human Services will be notified of any positive West Nile Virus
results, and they may contact you to conduct a confidential interview to help track community
risk to WNV.
The Cord Blood Bank may also contact you directly, using the contact information you provide,
in order to obtain updated information about your child's health regarding inherited
disorders and/or communicable diseases, or to request additional information or clarification
of information contained in the Cord Blood Bank file. If you become aware of any changes in
your baby's health which may affect the suitability of the donated cord blood unit for
transplantation, it is important that you contact the Cord Blood Bank at 713-563-8000.
The cord blood will be tested and frozen. Cord blood units that meet clinical specifications
will be stored in the MD Anderson Cord Blood Bank, listed on the stem cell donor registries
and may be released to MD Anderson or other institutions in the US or around the world
following established criteria for bone marrow transplant donors, for a fee to cover handling
charges. These institutions will use the cord blood for patients needing a bone marrow
transplant. Any fresh or stored cord blood units donated to the Cord Blood Bank that do not
meet all the clinical specifications (for example, if they are too small or have bacterial
contamination), and cannot be used for patients needing a bone marrow transplant, they may be
discarded or used for research or in studies to improve the cord blood banking procedures,
either at MD Anderson or at other institutions. Before your cord blood can be used for
research, the people doing the research must get specific approval from the Institutional
Review Board (IRB) of MD Anderson or the IRB of the institution where the research will be
performed. The IRB is a committee made up of doctors, researchers, and members of the
community. The IRB is responsible for protecting the participants involved in research
studies and making sure all research is done in a safe and ethical manner. All research
performed at MD Anderson, including research involving your cord blood from this bank, must
first be approved by the IRB.
The cord blood units will be used on a first come, first served basis. At the time of
donation, you will be given the address and phone number of the MD Anderson Cord Blood Bank.
In the unlikely event that you or another immediate family member develop a disease which
would require the use of your donated cord blood, it may be released to you on the same basis
that it would be provided to other qualifying patients, if it is still under the control of
the MD Anderson Cord Blood Bank and has not already been committed to a patient. You should
contact the MD Anderson Cord Blood Bank within one month of collection if you wish to have
your donated cord blood unit destroyed. If requested, the research staff will destroy your
cord blood unit if it has not been used for research, Cord Blood Bank validation studies or
quality control. After this one month period has passed, your cord blood unit will be made
available for patient use and you will be unable to request that it be destroyed.
This is an investigational study.
Up to 250,000 women will take part in this study. All will be enrolled through MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00766883 -
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT06148610 -
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
|
||
Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
Completed |
NCT02564458 -
Fitness in Allogeneic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01714557 -
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00701688 -
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Completed |
NCT00023530 -
Blood and Marrow Transplant Clinical Research Network
|
N/A | |
Recruiting |
NCT04092309 -
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
|
N/A | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT02663622 -
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
|
Phase 2 | |
Recruiting |
NCT04937634 -
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT04203108 -
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
|
Phase 4 | |
Completed |
NCT03654599 -
Effects of Digital Stories Intervention on Psychosocial Well-being
|
N/A | |
Withdrawn |
NCT03279133 -
Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.
|
Phase 4 | |
Completed |
NCT05151406 -
Myths and Misconceptions About HSCT in a Limited Resource Region
|
N/A | |
Completed |
NCT02241005 -
Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci
|
N/A | |
Recruiting |
NCT03689465 -
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
|
Phase 4 | |
Recruiting |
NCT04868786 -
Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT03010579 -
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation
|
Phase 4 |